Page 27 - IJB-6-4

Shpichka, et al.
complex systems to study this virus and perform coronavirus 2. Science, 368(6494):1016–20. DOI: 10.1126/
drug screening, this multidisciplinary approach can science.abb7015.
be a new chapter in antiviral research in view of the 5. Le Bras A, 2020, SARS-CoV-2 Causes COVID-19-Like
outstanding achievements described in this review. Disease in Cynomolgus Macaques. Lab Anim, 49(6):174.
DOI: 10.1038/s41684-020-0571-8.
Acknowledgments 6. Rockx B, Kuiken T, Herfst S, et al., 2020, Comparative

This work was supported by the Russian Science Pathogenesis of COVID-19, MERS, and SARS in a
Foundation (18-15-00407, Introduction and Section Nonhuman Primate Model. Science, 368(6494):1012–5.
4.1), Russian Foundation for Basic Research (18- 7. Lutz C, Maher L, Lee C, et al., 2020, COVID-19 Preclinical
Models: Human Angiotensin-Converting Enzyme 2
29-06059, Section 2; 20-04-60063, Section 4.2 Transgenic Mice. Hum Genomics, 14:20. DOI: 10.1186/
and 4.3), and Russian academic excellence project s40246-020-00272-6.
5–100 (Section 3 and Conclusions).
8. Monteil V, Kwon H, Prado P, et al., 2020, Inhibition of
Conflict of interest SARS-CoV-2 Infections in Engineered Human Tissues Using
Clinical-Grade Soluble Human ACE2. Cell, 181(4):905–13.
The authors declare that they have no conflict of DOI: 10.1016/j.cell.2020.04.004.
interest. 9. Lindesmith L, Moe C, Marionneau S, et al., 2003, Human
Susceptibility and Resistance to Norwalk Virus Infection. Nat
Author contributions Med, 9(5):548–53. DOI: 10.1038/nm860.

A.Sh., E.G., V.M., and P.S. outlined the manuscript. 10. DeVincenzo JP, Wilkinson T, Vaishnaw A, et al., 2010, Viral
P.B. and M.P. contributed to Section 2.3 and 3 (except Load Drives Disease in Humans Experimentally Infected
3.2), D.B. – Section 2.1, N.K. – Section 2.2, M.V., with Respiratory Syncytial Virus. Am J Respir Crit Care
E.Z., and N.K.R. – Section 3.2, and A.S. – Section Med, 182(10):1305–14. DOI: 10.1164/rccm.201002-0221oc.
4 and 5, A.Sv. – Section 1 and 2.3. I.Z. drafted and 11. Memoli MJ, Shaw PA, Han A, et al., 2016, Evaluation of
prepared Figure 3, including its description; D.B., Antihemagglutinin and Antineuraminidase Antibodies as
E.Z., and N.K.R. – Figures 1 and 2. A.S. drafted the Correlates of Protection in an Influenza A/H1N1 Virus
manuscript with primary editing and revision support Healthy Human Challenge Model. MBio, 7(2):1–12. DOI:
from A.Sv., P.S., and V.M. A.Sh., A.Sv., D.B., E.Z., 10.1128/mbio.00417-16.
E.G., and N.K.R. prepared the paper’s revision to 12. Wilkinson TM, Li CK, Chui CS, et al., 2012, Preexisting
address reviewers’ comments. A.Sv., P.S., and E.G. Influenza-Specific CD4 + T Cells Correlate with Disease
coordinated the manuscript preparation. All authors Protection against Influenza Challenge in Humans. Nat Med,
read and approved the final manuscript. 18(2):274–80. DOI: 10.1038/nm.2612.
13. He XS, Holmes TH, Zhang C, et al., 2006, Cellular Immune
References Responses in Children and Adults Receiving Inactivated or
Live Attenuated Influenza Vaccines. J Virol, 80(23):11756–
1. Choong YYC, Tan HW, Patel DC, et al., 2020, The Global 66. DOI: 10.1128/jvi.01460-06.
Rise of 3D Printing During the COVID-19 Pandemic. Nat 14. Huang KY, Li CK, Clutterbuck E, et al., 2014, Virus-Specific
Rev Mater,1–3. DOI: 10.1038/s41578-020-00234-3. Antibody Secreting Cell, Memory B-Cell, and Sero-antibody
2. Hossein-Khannazer N, Shokoohian B, Shpichka A, et al., Responses in the Human Influenza Challenge Model. J Infect
2020, Novel Therapeutic Approaches for Treatment of Dis, 209(9):1354–61. DOI: 10.1093/infdis/jit650.
COVID-19. J Mol Med, 3:1–15. DOI: 10.1007/s00109-020- 15. Larsen CP, Whitehead SS, Durbin AP, 2015, Dengue
01927-6. Human Infection Models to Advance Dengue Vaccine
3. Park SJ, Yu KM, Kim YI, et al., 2020, Antiviral Efficacies Development. Vaccine, 33(50):7075–82. DOI: 10.1016/j.
of FDA-Approved Drugs against SARS-COV-2 Infection in vaccine.2015.09.052.
Ferrets. MBio, 11(3):e01114–20. DOI: 10.1128/mbio.01114-20. 16. Kirkpatrick BD, Whitehead SS, Pierce KK, et al., 2016, The Live
4. Shi J, Wen Z, Zhong G, et al., 2020, Susceptibility of Ferrets, Attenuated Dengue Vaccine TV003 Elicits Complete Protection
Cats, Dogs, and other Domesticated Animals to SARS- Against Dengue in a Human Challenge Model. Sci Transl Med,

International Journal of Bioprinting (2020)–Volume 6, Issue 4 23